All In Biotech

Drug Trial Radar · NCT01760005

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 490 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

490

Planned (sponsor's estimate)

Start

Dec 2012

Primary completion

Apr 2028

Study completion Jul 2028

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eli Lilly and Company; Hoffmann-La Roche; Alzheimer's Association; National Institute on Aging (NIA); Avid Radiopharmaceuticals; Accelerating Medicines Partnership (AMP); Eisai Inc.; Janssen, LP
First posted
Jan 3, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.

Conditions

  • Alzheimers Disease
  • Dementia
  • Alzheimers Disease, Familial

Interventions

  • GantenerumabDrug

    Subcutaneously every 4 weeks at escalating doses

  • SolanezumabDrug

    Intravenous infusion every 4 weeks at escalating doses

  • Matching Placebo (Gantenerumab)Drug

    Subcutaneous injection of placebo every 4 weeks

  • Matching Placebo (Solanezumab)Drug

    Intravenous infusion of placebo every 4 weeks

  • GantenerumabDrug

    Open-label administered Subcutaneously every 4 weeks at escalating doses

  • E2814Drug

    Administered intravenously in a blinded fashion

  • LecanemabDrug

    Administered intravenously

  • Matching Placebo (E2814)Drug

    Placebo administered intravenously in a blinded fashion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assess cognitive efficacy in individuals with mutations causing dominantly inherited AD as measured by the change from baseline in the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE)Time frame: Baseline and Weeks 52, 104, 156, and 208

Locations

38 sites in 15 countries. Site status is shown where the registry gives one.

  • University of Alabama in Birmingham

    Birmingham, Alabama

  • University of California San Diego Medical Center

    La Jolla, California

  • USC Keck School of Medicine

    Los Angeles, California

  • Yale University School of Medicine

    New Haven, Connecticut

  • Emory University

    Atlanta, Georgia

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • Washington University in St. Louis

    St Louis, Missouri

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Butler Hospital

    Providence, Rhode Island

  • Kerwin Medical Center

    Dallas, Texas

  • University of Washington

    Seattle, Washington

  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI

    Ciudad Autonoma de Buenos Aire, Argentina

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia

  • Alzheimer's Research Australia

    Melbourne, Victoria, Australia

  • The McCuster Foundation of Alzheimer's Disease Research

    Nedlands, Western Australia, Australia

  • Hospital das Clínicas da Faculdade de Medicina da USP

    São Paulo, Brazil

  • CHU de Quebec - Hôpital de l' Enfant Jésus

    Québec, Canada

  • UBC Hospital

    Vancouver, British Columbia, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

  • McGill Center for Studies in Aging

    Verdun, Quebec, Canada

  • Grupo de Neurociencias Sede de la Universidad de Antioquia

    Medellín, Colombia

  • CHU de Toulouse - Hôpital Purpan

    Toulouse, Haute Garonne, France

  • Hopital Roger Salengro - CHU Lille

    Lille, Nord, France

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, Paris, France

  • Hopital Neurologique Pierre Wertheimer

    Bron, Rhone, France

  • CHU de Rouen - Hôpital Charles Nicolle

    Rouen, Seine Maritime, France

  • Universitaetsklinikum Tubingen

    Tübingen, Baden-Wurttemberg, Germany

  • LMU-Campus Grosshadern

    Munich, Bavaria, Germany

  • St Vincent's University Hospital

    Dublin, Dublin, Ireland

  • IRCCS Centro San Giovanni di Dio Fatebenefratelli

    Brescia, Italy

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy

  • Niigata University Medical & Dental Hospital

    Niigata, Niigata, Japan

  • University of Tokyo Hospital

    Bunkyō City, Tokyo-To, Japan

  • Brain Research Center

    Amsterdam, Netherlands

  • University of Puerto Rico, School of Medicine

    San Juan, Puerto Rico, Puerto Rico

  • Hospital Clínic I Provincial de Barcelona

    Barcelona, Barcelona, Spain

  • The National Hospital for Neurology and Neurosurgery

    London, Greater London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.